Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high ...

Johnson & Johnson announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year ...

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...

Johnson & Johnson's Inlexzo shows promising survival rates in BCG-unresponsive NMIBC patients. Read more here.

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort ...

I am a highly creative hypochondriac. Using medical expertise I obtained from the internet, I have successfully misdiagnosed ...

The Endoscopy Procedures market is growing due to advancements in imaging technology, AI integration, and increased clinical applications in various domains such as GI and pulmonology. Regional ...

Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.

A spokesperson for the WHSCT said: ““We acknowledge that gynaecology waiting lists in the Western Trust, and regionally, are ...

FDA approves pembrolizumab and enfortumab vedotin for neoadjuvant and adjuvant treatment of cisplatin-ineligible muscle-invasive bladder cancer.